Literature DB >> 7908116

Is SDZ NVI-085 an alpha 1-adrenoceptor subtype-selective agonist?

R Büscher1, P A Insel, M C Michel.   

Abstract

SDZ NVI-085 has been proposed to be a centrally acting agonist with selectivity for some alpha 1-adrenoceptor subtypes. We have investigated its selectivity and efficacy at alpha 1-adrenoceptor subtypes in rat tissues and at cloned subtypes. SDZ NVI-085 had higher affinity for chloro-ethylclonidine-insensitive (alpha 1A-like) than for -sensitive (alpha 1B) alpha 1-adrenoceptors in rat kidney but not in cerebral cortex. SDZ NVI-085 recognized cloned alpha 1-adrenoceptor subtypes expressed in COS cells with the order of potency bovine alpha 1C > rat alpha 1A/D > rat alpha 1B. Relative to 100 microM noradrenaline, SDZ NVI-085 was only a partial agonist for stimulation of inositol phosphate formation in rat kidney and inhibited noradrenaline-stimulated inositol phosphate formation in native and chloroethylclonidine-treated tissue. We conclude that SDZ NVI-085 discriminates among multiple alpha 1-adrenoceptor subtypes and is a partial agonist at rat renal alpha 1A- and alpha 1B-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908116     DOI: 10.1016/0024-3205(94)00502-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Comparison of guinea-pig, bovine and rat alpha 1-adrenoceptor subtypes.

Authors:  R Büscher; C Heeks; K Taguchi; M C Michel
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

2.  Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; P A Insel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.